Resilience Capacity Update October 2024: Large Molecule Drug Substance

Here, we present a comprehensive overview of our Biologics & Vaccines capabilities across our premier North American sites. Since our founding in 2020, Resilience has focused on advancing biomanufacturing technologies to increase access to complex medicines for patients worldwide. With a robust network spanning six U.S. states and Canada, we deliver cutting-edge solutions for both established and emerging therapies.

Watch below as Evan Pasenello, Business Head of Biologics & Vaccines, shares insights on how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs from start to finish.